UBS AM
AVBP icon

UBS AM’s ArriVent BioPharma AVBP Stock Holding History

UBS AM’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$395K Hold
11,357
– – ﹤0.01% 2598
2026
Q1 		$262K Buy
11,357
+350
+3% +$7.91K ﹤0.01% 2679
2025
Q4 		$221K Buy
11,007
+45
+0.4% +$937 ﹤0.01% 2452
2025
Q3 		$202K Sell
10,962
-18,593
-63% -$365K ﹤0.01% 2223
2025
Q2 		$643K Buy
+29,555
New +$614K ﹤0.01% 2463
2025
Q1 		– Sell
-8,165
Closed -$218K – 2707
2024
Q4 		$218K Buy
+8,165
New +$234K ﹤0.01% 2633

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS AM's AVBP Position: Q2 2026 in Review

UBS AM held its ArriVent BioPharma (AVBP) position steady in Q2 2026 at 11,357 shares worth $395K. The position accounts for ﹤0.01% of the portfolio, ranked #2598.

UBS AM first reported a position in AVBP in Q4 2024 and has held it in 6 quarters since. The position peaked at $643K in Q2 2025. 158 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • UBS AM held 11,357 shares of ArriVent BioPharma worth $395K as of Q2 2026.
  • UBS AM left its ArriVent BioPharma share count unchanged in Q2 2026.
  • ArriVent BioPharma made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2598 holding.
  • UBS AM first reported a position in ArriVent BioPharma in Q4 2024 and has held it in 6 quarters since.
  • UBS AM's ArriVent BioPharma position peaked at $643K in Q2 2025.
  • 158 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.